U.S. markets open in 2 hours 56 minutes
  • S&P Futures

    3,829.00
    -13.50 (-0.35%)
     
  • Dow Futures

    30,697.00
    -145.00 (-0.47%)
     
  • Nasdaq Futures

    13,521.00
    +35.50 (+0.26%)
     
  • Russell 2000 Futures

    2,127.20
    -18.60 (-0.87%)
     
  • Crude Oil

    52.86
    +0.25 (+0.48%)
     
  • Gold

    1,841.90
    -9.00 (-0.49%)
     
  • Silver

    25.34
    -0.20 (-0.78%)
     
  • EUR/USD

    1.2129
    -0.0040 (-0.33%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    24.99
    +1.80 (+7.76%)
     
  • GBP/USD

    1.3731
    -0.0001 (-0.01%)
     
  • USD/JPY

    103.8010
    +0.1740 (+0.17%)
     
  • BTC-USD

    31,510.32
    -847.23 (-2.62%)
     
  • CMC Crypto 200

    633.53
    -6.39 (-1.00%)
     
  • FTSE 100

    6,613.14
    -40.87 (-0.61%)
     
  • Nikkei 225

    28,635.21
    +89.03 (+0.31%)
     

Tandem Diabetes Care to Announce Third Quarter 2020 Financial Results on November 5, 2020

·2 min read

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2020 results after the financial markets close on Thursday, November 5, 2020. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2020 financial and operating results.

Conference Call/Webcast Details:
Date:
November 5, 2020
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Toll Free Dial-In Number: (855) 427-4396
International Dial-In Number: (484) 756-4261
Conference ID: 8072078
Webcast Link: https://edge.media-server.com/mmc/p/mp7mdi2q

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring, and optional automated insulin delivery technology. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at www.linkedin.com/company/TandemDiabetes.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005093/en/

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com